Kósa F, Kunovszki P, Borsi A, et al. - In this nationwide, retrospective study involving 476 infliximab and 397 adalimumab patients, researchers provided representative real-world data on anti-TNFα drug sustainability, prevalence and predictors of anti-TNFα dose escalation. Using the administrative claims database of the Hungarian National Health Insurance Fund, patients receiving infliximab or adalimumab therapy between 2013 and 2016 were involved. In 7%, 9% and 22% of patients receiving originator/biosimilar infliximab and adalimumab during the complete follow-up, respectively, dose escalation was noted. Findings suggested an association of dose escalation with shorter disease duration and corticosteroid use. In this real-world administrative database study, dose-escalation rates were lower for both adalimumab and infliximab vs published data. Rates of drug retention are adequate overall, with no apparent difference between the legacy and infliximab biosimilar.